Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course versus long-course preoperative chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma
2024-519031-42-00Phase 3Authorised
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, fluorouracil, oxaliplatin, folinic acid, paclitaxel and 3 more in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Associazione Italiana per lo Studio del Pancreas. Primary endpoint: Event-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
irinotecanfluorouraciloxaliplatinfolinic acidpaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-519031-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519031-42-00.